久久一区二区三区四区_欧美高清dvd_日韩欧美在线看_国产精品欧美一区二区_av天天看_欧美精品免费观看二区

加拿大Sophiris Bio  
Protox Therapeutics Inc. (溫哥華，Vancouver)宣布公司就PRX302藥物項目己向美國FDA提出攝護腺癌治療藥物的研究中新藥申請(investigational new drug， IND)。一旦在FDA的IND案通過，公司預期便可以在下一年進行復發型部位固定攝護腺癌臨床第一期測試。

2012年加拿大Protox Therapeutics Inc 改名為Sophiris Bio
 

Protox Therapeutics uses genetic engineering to transform naturally occurring proteins into novel targeted therapeutics for the treatment of prostate diseases and various cancers. Protox is advancing a pipeline of clinical-stage product candidates derived from its PORxin? and INxin? technology platforms. Protox’s lead drugs currently in clinical development include PRX302 for the treatment of benign prostatic hyperplasia (BPH, commonly known as enlarged prostate) and localized prostate cancer, as well as PRX321 for primary brain cancer (glioblastoma multiforme and astrocytoma).